Trial Profile

Cediranib In Recurrent Cervical Cancer - A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Apr 2019 Results identifying a minimally-invasive biomarker predicting benefit from cediranib pre-treatment published in the British Journal of Clinical Pharmacology.
13 Oct 2015 Results published in the Lancet Oncology
25 Aug 2012 Accrual to date is 86% according to United Kingdom Clinical Research Network.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com